Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02067416Phase 2Withdrawn

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

Role: lead

NCT01931163Phase 2Completed

NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer

Role: lead

NCT02073916Phase 1Completed

T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer

Role: lead

NCT02725541Phase 2Withdrawn

Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer

Role: lead

All 4 trials loaded